Sanofi (SNY) Receives “Neutral” Rating from JPMorgan Chase & Co.

Sanofi (NYSE:SNY)‘s stock had its “neutral” rating reiterated by analysts at JPMorgan Chase & Co. in a note issued to investors on Monday.

Several other research firms have also issued reports on SNY. Guggenheim initiated coverage on shares of Sanofi in a research report on Monday, October 8th. They issued a “neutral” rating on the stock. Zacks Investment Research lowered shares of Sanofi from a “hold” rating to a “sell” rating in a research report on Tuesday, October 16th. ValuEngine raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Wednesday, October 17th. Wolfe Research initiated coverage on shares of Sanofi in a research report on Tuesday, October 23rd. They issued a “market perform” rating on the stock. Finally, Barclays raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Thursday, November 1st. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. Sanofi has an average rating of “Hold” and a consensus target price of $50.00.

SNY opened at $42.44 on Monday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The stock has a market capitalization of $108.88 billion, a price-to-earnings ratio of 13.56, a P/E/G ratio of 2.41 and a beta of 0.67. Sanofi has a twelve month low of $37.43 and a twelve month high of $45.86.

Sanofi (NYSE:SNY) last released its earnings results on Wednesday, October 31st. The company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.98 by $0.09. The firm had revenue of $9.39 billion for the quarter, compared to analysts’ expectations of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.71 earnings per share. As a group, research analysts anticipate that Sanofi will post 3.1 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of SNY. Teachers Advisors LLC bought a new stake in Sanofi during the 3rd quarter worth approximately $31,557,000. FMR LLC increased its holdings in Sanofi by 7.5% during the 3rd quarter. FMR LLC now owns 8,527,983 shares of the company’s stock worth $380,945,000 after acquiring an additional 595,125 shares during the period. TIAA CREF Investment Management LLC bought a new stake in Sanofi during the 3rd quarter worth approximately $26,081,000. Tocqueville Asset Management L.P. increased its holdings in Sanofi by 555.7% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 608,836 shares of the company’s stock worth $50,014,000 after acquiring an additional 515,986 shares during the period. Finally, Sofinnova Ventures Inc bought a new stake in Sanofi during the 3rd quarter worth approximately $18,438,000. 7.04% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: Conference Calls

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply